Glypressin

Glypressin is an injectable solution that contains the vasopressin analog terlipressin acetate as its active ingredient. It is supplied in a sterile liquid form for intravenous administration and is marketed in the European Union as a prescription‑only medication. As a selective V1‑receptor agonist, Glypressin produces vasoconstriction that can lower portal venous pressure and support renal perfusion in specific clinical settings and improve hemodynamic stability for critically ill patients.

Glypressin is indicated for several acute conditions where rapid vasoconstriction is required. These uses reflect its ability to raise systemic vascular resistance and enhance organ perfusion. - Management of acute esophageal variceal bleeding in patients with portal hypertension. - Treatment of hepatorenal syndrome type 1 to improve renal function. - Off‑label use for selected cases of septic shock when conventional therapy is insufficient. - Support of hemodynamics during liver transplantation procedures. - Adjunct therapy in severe hypotension associated with advanced liver disease.

The safety profile of Glypressin includes both frequent, typically mild reactions and less common, potentially serious events.

Common: - Transient headache or dizziness, usually resolving after infusion cessation. - Nausea, vomiting, or abdominal discomfort that may be mild and self‑limited. - Flushing, warmth, or mild skin erythema at the infusion site. - Mild increase in serum sodium levels observed during therapy.

Serious: - Severe hypertension or hypertensive crisis that may require antihypertensive treatment. - Cardiac arrhythmias, including tachycardia or atrial fibrillation, potentially needing monitoring. - Ischemic complications such as myocardial infarction, limb ischemia, or mesenteric ischemia. - Acute renal failure or worsening renal function, especially in patients with pre‑existing kidney disease.

When prescribing Glypressin, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate use. - Assess baseline blood pressure; avoid use in patients with uncontrolled hypertension. - Evaluate cardiac history, as Glypressin may exacerbate ischemic heart disease. - Monitor renal function before and during therapy, especially in those with existing kidney impairment. - Use cautiously in patients with peripheral vascular disease due to risk of limb ischemia. - Consider potential fetal risk; Glypressin is contraindicated in pregnancy unless benefits outweigh unknown risks. - Review concomitant vasoconstrictive agents to prevent additive hypertensive effects.

Glypressin can interact with other medications that influence vascular tone, cardiac rhythm, or renal function.

Avoid: - Concurrent use with other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) that may cause severe hypertension. - Combination with monoamine oxidase inhibitors or serotonergic agents, which could increase risk of vasospasm. - Simultaneous administration with QT‑prolonging drugs, as combined effects may precipitate arrhythmias.

Use with caution: - Co‑administration with beta‑blockers, which may mask tachycardia signs. - Concurrent diuretics, requiring close monitoring of electrolytes and fluid balance. - Combination with anticoagulants, as ischemic complications may be amplified. - Concomitant corticosteroids, which can enhance fluid retention and raise blood pressure. - Use with drugs affecting hepatic metabolism (e.g., CYP450 inhibitors) because altered clearance may modify drug response.